Eagle Pharmaceuticals to Host Third Quarter 2023 Financial Results on November 9, 2023
November 08 2023 - 8:30AM
Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq:
EGRX) today announced that the Company will release its third
quarter 2023 financial results on Thursday, November 9, 2023,
before the market opens.
Scott Tarriff, President and Chief Executive Officer, and Brian
Cahill, Chief Financial Officer, will host a conference call to
discuss the results as follows:
DateTimeToll
free (U.S.)International |
Thursday,
November 9, 2023 8:30 a.m. ET800-343-4136203-518-9843 |
|
|
Webcast (live
and replay) |
www.eagleus.com, under the “Investor Relations” section |
|
|
A replay of the conference call will be available for two weeks
after the call's completion by dialing 888-562-0859 (U.S.) or
402-220-7342 (International) and entering conference call ID
EGRXQ323. The webcast will be archived for 30 days at the
aforementioned URL.
About Eagle Pharmaceuticals,
Inc. Eagle is a fully integrated
pharmaceutical company with research and development, clinical,
manufacturing and commercial expertise. Eagle is committed to
developing innovative medicines that result in meaningful
improvements in patients’ lives. Eagle’s commercialized products
include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM®
(Japan), and BYFAVO® and BARHEMSYS® through its wholly owned
subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic
critical care pipeline includes product candidates with the
potential to address underserved therapeutic areas across multiple
disease states, and the company is focused on developing medicines
with the potential to become part of the personalized medicine
paradigm in cancer care. Additional information is available on
Eagle’s website at www.eagleus.com.
Contact:Investor Relations for Eagle
Pharmaceuticals, Inc:Lisa M. WilsonT: 212-452-2793E:
lwilson@insitecony.com
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
From Apr 2023 to Apr 2024